| 1. |
- Mauri, Davide, et al.
(författare)
-
Cancer pain ... who cares? : International and national patterns of evidence-based global guide-lines recommendations for physicians on the Web (2011 vs. 2018)
- 2020
-
Ingår i: Journal of B.U.ON. (JBUON). - 1107-0625 .- 2241-6293. ; 25:1, s. 62-73
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: Although pain is a common event during treatment of cancer, its assessment and management remains suboptimal in everyday clinical practice at global level.Methods: Considering both the important role of Internet in daily life and that clinical guidelines are important for translating evidence in clinical practice, we performed a prospective study to scrutinize the magnitude of updated evidence-based cancer-pain guideline recommendation for physicians on the web. Changes over-time at a global level were scrutinized at two time points: 2011 for baseline and 2018 at first follow-up. Both anesthesiology and oncology societies were analyzed.Results: In 2011 we scrutinized 181,00 WebPages and 370 eligible societies were identified; 364 of these were eligible for analyses both in 2011 and 2018. The magnitude of cancer pain updated and evidence-based guideline recommendations on the web for health care providers was extremely low at global level and at any time point considered 1.1% (4/364) in 2011 and 4.7% (17364) in 2018. Continental and intercontinental patterns, National's highest developmental index, oncology tradition and economic-geographic areas were not found to influence cancer pain web-guideline provision. In 2018, pain & supportive care societies provided the highest rate of updated evidence-based cancer-pain guidelines for clinicians. Only 3/25 medical oncology societies and 1/34 radiation oncology societies, provided own or e-link (to other societies) evidence-based guidelines in their websites.Conclusions: Major medical oncology and radiation oncology societies - at global level - fail to produce updated cancer pain recommendations for their physicians, with most of these providing no or inconsistent or outdated guidelines.
|
|
| 2. |
- Anyfantis, Dimitrios I., et al.
(författare)
-
Growth, Magnetic Anisotropies and Exchange Bias of Thin Ni0.95Fe0.05/NiFeO Multilayers
- 2022
-
Ingår i: Coatings. - : MDPI AG. - 2079-6412. ; 12:5
-
Tidskriftsartikel (refereegranskat)abstract
- Ni0.95Fe0.05/NiFeO multilayers were fabricated by radio frequency magnetron sputtering and natural oxidation. Doping of Ni by only 5 at. % Fe results in enhanced layering quality as X-ray reflectivity reveals. Due to magnetostatic anisotropy, the multilayers were found to be in-plane magnetized. The influence of mild thermal annealing (T = 525 K) on the magnetic properties of NiFe/NiFeO multilayers is also investigated. Annealing results in the enhancement of perpendicular magnetic anisotropy, mainly due to an increase in the uniaxial volume anisotropy term. Temperature-dependent hysteresis measurements between 4-400 K revealed considerable enhancement of coercivity and appearance of exchange bias effect.
|
|
| 3. |
- Arnalds, Unnar B., et al.
(författare)
-
Thermal transitions in nano-patterned XY-magnets
- 2014
-
Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 105:4, s. 042409-
-
Tidskriftsartikel (refereegranskat)abstract
- We have fabricated ultra-thin disc shaped islands wherein shape anisotropy confines the moment to the island plane, creating XY-like superspins. At low temperatures, the superspins are blocked, and, as the temperature is increased, they undergo a transition into a superparamagnetic state. The onset of this dynamic superspin state scales with the diameter of the islands, and it persists up to a temperature governed by the intrinsic ordering temperature of the island material defining a range in temperature in which dynamic behavior of the magnetic islands can be obtained.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Baliakas, Panagiotis, 1977-, et al.
(författare)
-
Cytogenetic complexity in chronic lymphocytic leukemia : definitions, associations, and clinical impact
- 2019
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 133:11, s. 1205-1216
-
Tidskriftsartikel (refereegranskat)abstract
- Recent evidence suggests that complex karyotype (CK) defined by the presence of >= 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with >= 5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and 112,119 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hyper-mutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with 112,119, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with >= 5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Chatzikonstantinou, T, et al.
(författare)
-
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- 2021
-
Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 3635:312, s. 3444-3454
-
Tidskriftsartikel (refereegranskat)abstract
- Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
|
|
| 10. |
|
|
